Quantification and Dosimetric Impact of Normal Organ Motion During Adaptive Radiation Therapy Planning Using a 1.5 Tesla Magnetic Resonance–Equipped Linear Accelerator (MR-Linac)

IF 2.2 Q3 ONCOLOGY

Advances in Radiation Oncology Pub Date : 2025-04-11 DOI:10.1016/j.adro.2025.101758

David Wittmann MD , Eric S. Paulson PhD , Anjishnu Banerjee PhD , Leou Ismael Banla MD, PhD , Christopher Schultz MD , Musaddiq Awan MD , Xinfeng Chen PhD , Eenas A. Omari PhD , Michael Straza MD, PhD , X. Allen Li PhD , Beth Erickson MD , William A. Hall MD

{"title":"Quantification and Dosimetric Impact of Normal Organ Motion During Adaptive Radiation Therapy Planning Using a 1.5 Tesla Magnetic Resonance–Equipped Linear Accelerator (MR-Linac)","authors":"David Wittmann MD , Eric S. Paulson PhD , Anjishnu Banerjee PhD , Leou Ismael Banla MD, PhD , Christopher Schultz MD , Musaddiq Awan MD , Xinfeng Chen PhD , Eenas A. Omari PhD , Michael Straza MD, PhD , X. Allen Li PhD , Beth Erickson MD , William A. Hall MD","doi":"10.1016/j.adro.2025.101758","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Patients receiving adaptive magnetic resonance guided radiation therapy (MRgRT) undergo contour modification prior to treatment delivery, which takes 15 to over 60 minutes. We hypothesized that during the time required to create an adaptive MRgRT plan, organ movement will result in dosimetric changes to regional organs at risk (OARs). This study quantifies the dosimetric impact of OAR motion during the time required to perform adaptive MRgRT.</div></div><div><h3>Methods and Materials</h3><div>Thirty-one patients with pancreatic adenocarcinoma, prostate adenocarcinoma, hepatocellular carcinoma, and oligo-metastases who received MRgRT using a 1.5 Tesla MR-Linac were prospectively enrolled in an open registry imaging trial (NCT03500081). Two magnetic resonance imaging (MRI) studies were acquired predelivery for each MRgRT treatment fraction: an initial “pretreatment” MRI (input to the adaptive evaluation with or without recontouring and replanning process), and a second “verification MRI” (acquired after the recontouring and adaption process and immediately before treatment delivery or “beam-on”). On the verification MRI, normal organs were recontoured offline. Recontoured normal organs included the colon, duodenum, small bowel, and stomach. Differences in OARs between organ positions represented the normal organ movement during the time required for plan adaption. Maximum dose (Dmax), volumetric (V) 0.5 cubic centimeter dose (D0.5cc), 3000 cGy (V30), and 2000 cGy (V20) were calculated from the recontoured verification MRI.</div></div><div><h3>Results</h3><div>Differences in Dmax, per fraction, for the listed normal organs were as follows: colon/rectum 239.50 cGy (<em>P</em> = .09), duodenum 136.40 cGy (<em>P</em> = .05), small bowel 488.27 cGy (<em>P</em> < .01), and stomach 95.92 (<em>P</em> = .17). Small bowel demonstrated a significant difference in Dmax, D0.5cc, and V30.</div></div><div><h3>Conclusions</h3><div>Statistically significant differences in small bowel doses are demonstrated as a result of motion during the timing required for adaptive MRgRT. These results reflect the importance of verifying MRI acquisition during adaptive MRgRT to confirm the location of OARs. They also identify the necessity of strategies to account for the dynamic nature of regional OARs.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"10 5","pages":"Article 101758"},"PeriodicalIF":2.2000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109425000466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Patients receiving adaptive magnetic resonance guided radiation therapy (MRgRT) undergo contour modification prior to treatment delivery, which takes 15 to over 60 minutes. We hypothesized that during the time required to create an adaptive MRgRT plan, organ movement will result in dosimetric changes to regional organs at risk (OARs). This study quantifies the dosimetric impact of OAR motion during the time required to perform adaptive MRgRT.

Methods and Materials

Thirty-one patients with pancreatic adenocarcinoma, prostate adenocarcinoma, hepatocellular carcinoma, and oligo-metastases who received MRgRT using a 1.5 Tesla MR-Linac were prospectively enrolled in an open registry imaging trial (NCT03500081). Two magnetic resonance imaging (MRI) studies were acquired predelivery for each MRgRT treatment fraction: an initial “pretreatment” MRI (input to the adaptive evaluation with or without recontouring and replanning process), and a second “verification MRI” (acquired after the recontouring and adaption process and immediately before treatment delivery or “beam-on”). On the verification MRI, normal organs were recontoured offline. Recontoured normal organs included the colon, duodenum, small bowel, and stomach. Differences in OARs between organ positions represented the normal organ movement during the time required for plan adaption. Maximum dose (Dmax), volumetric (V) 0.5 cubic centimeter dose (D0.5cc), 3000 cGy (V30), and 2000 cGy (V20) were calculated from the recontoured verification MRI.

Results

Differences in Dmax, per fraction, for the listed normal organs were as follows: colon/rectum 239.50 cGy (P = .09), duodenum 136.40 cGy (P = .05), small bowel 488.27 cGy (P < .01), and stomach 95.92 (P = .17). Small bowel demonstrated a significant difference in Dmax, D0.5cc, and V30.

Conclusions

Statistically significant differences in small bowel doses are demonstrated as a result of motion during the timing required for adaptive MRgRT. These results reflect the importance of verifying MRI acquisition during adaptive MRgRT to confirm the location of OARs. They also identify the necessity of strategies to account for the dynamic nature of regional OARs.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

4.60

自引率

4.30%

发文量

208

审稿时长

98 days

期刊介绍： The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.